Combined therapy may improve clinical responses for endometrial, colorectal and gastric tumors
A study at The University of Texas MD Anderson Cancer Center discovered a novel therapeutic vulnerability for patients who have tumors caused by a genetic misfire in the DNA mismatch repair (MMR) pathway, a system for repairing genetic aberrations. Study findings were published in the Feb. 27 online issue of Cancer Cell.
When tumors lose MMR function, they acquire numerous mutations throughout their DNA which can promote cancer...
Osteosarcoma profiling reveals why immunotherapy remains ineffective
Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the traditionally...
MD Anderson announces strategic collaboration with Denali Therapeutics to research and develop targeted therapies for neurodegenerative diseases
The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration with Denali Therapeutics Inc. to develop...
MD Anderson receives more than $20 million in CPRIT funding
The University of Texas MD Anderson Cancer Center today was awarded more than $20 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support research, clinical translation, prevention and recruitment efforts. In total, MD Anderson received 28% of the $78 million in awards announced by CPRIT.
MD Anderson awards included $12.2 million for individual investigator awards, $5.7 million for individual...
Houston Dash join Dynamo, MD Anderson in Making Cancer History
The University of Texas MD Anderson Cancer Center today announced the Houston Dash will join the institution's efforts toward one goal...
Absent p53, oral cancers recruit and reprogram nerves to fuel tumor growth
Loss of an important tumor-suppressing gene allows head and neck cancer to spin off signals to nearby nerves, changing their function and...
CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric...
Study provides new understanding of mitochondria genome with potential for new avenues of treatment for multiple cancers
A study led by The University of Texas MD Anderson Cancer Center furthered understanding about mitochondria, the cell components known as...
MD Anderson supports World Cancer Day through dedication to eliminate cancer
The University of Texas MD Anderson Cancer Center honors World Cancer Day, Feb. 4, as the campaign celebrates 20 years of bringing awareness...